복막 투석 시장 : 제품 유형별, 치료법별, 환자 유형별, 용도별, 최종 사용자별 시장 예측(2026-2032년)

The Peritoneal Dialysis Market is projected to grow by USD 15.20 billion at a CAGR of 6.18% by 2032.

Peritoneal dialysis is gaining strategic relevance as health systems seek scalable, home-based treatment models for kidney failure. Chronic kidney disease affects more than 850 million people globally, according to widely cited nephrology estimates, and diabetes and hypertension remain the dominant drivers of progression to end-stage kidney disease.

The peritoneal dialysis market is shaped by demand for automated peritoneal dialysis, continuous ambulatory peritoneal dialysis, PD solutions, cyclers, catheters, transfer sets, and remote patient monitoring. Its value proposition is strongest where payers and providers prioritize patient autonomy, reduced in-center capacity pressure, continuity of care outside the hospital setting, and lower treatment burden for clinically suitable patients.

Transformative Shifts in the Peritoneal Dialysis Landscape

The peritoneal dialysis landscape is shifting from procedure-centric care to connected home therapy. Automated peritoneal dialysis cyclers, digital adherence tools, cloud-based treatment records, and telehealth-enabled nephrology follow-up are making PD more practical for patients, caregivers, and dialysis programs.

Policy is also accelerating change. Home dialysis incentives in mature markets, expanding nephrology infrastructure in emerging economies, and pressure to improve dialysis access are supporting broader PD adoption. However, peritonitis risk, training requirements, reimbursement variation, patient selection, caregiver availability, and supply chain resilience remain decisive barriers for market participants.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence peritoneal dialysis through predictive analytics, patient risk stratification, supply forecasting, and clinical workflow support. AI-enabled platforms can analyze treatment logs, ultrafiltration trends, alarms, blood pressure readings, laboratory results, and patient-reported symptoms to identify early signs of nonadherence, fluid imbalance, catheter issues, or infection risk.

The strongest near-term impact is operational rather than fully autonomous care. AI can help providers prioritize outreach, reduce avoidable escalation, improve inventory planning, and support personalized prescriptions when combined with clinician oversight, validated datasets, cybersecurity controls, and transparent governance aligned with medical device and health data regulations.

Key Regional Insights for Peritoneal Dialysis

Asia-Pacific is the fastest-evolving opportunity zone because China, India, Japan, South Korea, and Australia combine high CKD prevalence, aging populations, expanding home-care models, and growing investment in renal services. North America remains a premium market for automated peritoneal dialysis, supported by established reimbursement pathways, strong nephrology networks, national attention to home dialysis, and growing use of remote patient management.

Europe benefits from mature clinical guidelines, kidney registries, and public health systems that support home therapy, while Latin America shows selective growth led by Brazil and Mexico as dialysis access programs respond to diabetes- and hypertension-related kidney failure. The Middle East is investing in specialty care infrastructure across Gulf economies and broader tertiary-care networks, while Africa remains underpenetrated, with PD offering potential where hemodialysis capacity, electricity reliability, trained staffing, and transport access are constrained.

Key Group Insights Across Major Economic Blocs

ASEAN markets are increasingly relevant as governments expand universal health coverage, noncommunicable disease programs, and dialysis access, though adoption varies by training capacity, reimbursement, urban-rural infrastructure, and availability of sterile PD supplies. GCC countries are investing in advanced renal care and digital health, creating demand for premium cyclers, biocompatible PD fluids, specialty services, and home-care models aligned with high diabetes prevalence.

The European Union supports standardized quality expectations, regulatory oversight, and home-based care pathways, while BRICS economies represent large-volume opportunities tied to CKD burden, population scale, and infrastructure expansion. G7 markets lead in technology adoption, data integration, clinical governance, and reimbursement sophistication, and NATO-aligned healthcare systems increasingly emphasize supply continuity, domestic resilience, cybersecurity, and critical medical device security for essential therapies such as peritoneal dialysis.

Key Country Insights in Peritoneal Dialysis

The United States leads global innovation in home dialysis policy, remote monitoring, and automated peritoneal dialysis adoption, while Canada emphasizes equitable access across dispersed populations and uses provincial renal programs to coordinate kidney care. Mexico and Brazil are expanding renal replacement capacity as diabetes-related kidney disease rises, with PD adoption influenced by reimbursement design, clinical training, and supply availability.

The United Kingdom, Germany, France, Italy, and Spain benefit from organized nephrology systems, established clinical guidelines, and public or statutory reimbursement, though PD penetration differs by local commissioning, center experience, patient education, and clinical practice. Russia faces geographic access challenges that can favor home modalities, while infrastructure variation affects consistent uptake. China and India represent scale-driven growth due to large CKD populations and expanding insurance coverage, Japan and South Korea bring advanced device adoption and aging-population demand, and Australia combines a strong home dialysis culture with remote-care expertise for geographically dispersed communities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize patient training, infection prevention, catheter care, and digital support because technique survival and adherence determine long-term PD value. Organizations that combine reliable cyclers, biocompatible PD solutions, secure data platforms, clinical education, and responsive logistics will be better positioned in both mature and emerging markets.

Commercial strategy should align with reimbursement evidence, real-world outcomes, health equity goals, and provider workflow needs. Partnerships with nephrology clinics, home-care organizations, payers, kidney registries, and public health agencies can expand access while improving continuity of therapy, reducing avoidable hospital utilization, and strengthening confidence in home-based renal replacement therapy.

Research Methodology

This executive summary is based on secondary research from authoritative nephrology, public health, regulatory, and reimbursement sources, including global CKD burden literature, kidney registry evidence, clinical practice guidance, payer policy trends, and published information on home dialysis technologies.

The analysis applies triangulation across epidemiology, care delivery models, reimbursement structures, technology adoption, infection prevention standards, supply-chain considerations, and regional health-system capacity. Insights were validated for consistency with established clinical understanding of peritoneal dialysis, including CAPD, APD, PD fluid management, catheter care, peritonitis prevention, patient training, and remote patient monitoring.

Conclusion

Peritoneal dialysis is positioned for durable expansion as kidney failure prevalence rises and healthcare systems seek flexible, home-centered renal replacement therapy. The market opportunity is strongest where clinical quality, patient education, reimbursement alignment, infection control, and reliable supply chains converge.

Artificial intelligence, connected cyclers, and remote monitoring will not replace nephrologist-led care, but they can make peritoneal dialysis safer, more scalable, and more personalized. Market leaders that prove outcomes, simplify home therapy, protect patient data, and support equitable access will define the next phase of PD adoption.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Peritoneal Dialysis Market, by Product Type

• 7.1. Equipment
  • 7.1.1. Cyclers
  • 7.1.2. Catheters
  • 7.1.3. Transfer Sets
• 7.2. Consumables
  • 7.2.1. Dialysate Solutions
    • 7.2.1.1. Icodextrin-based
    • 7.2.1.2. Glucose-based
    • 7.2.1.3. Amino acid-based
  • 7.2.2. Tubing & Bags

8. Peritoneal Dialysis Market, by Modality

• 8.1. Continuous Ambulatory Peritoneal Dialysis (CAPD)
• 8.2. Automated Peritoneal Dialysis (APD)

9. Peritoneal Dialysis Market, by Patient Type

• 9.1. Adult Patients
• 9.2. Pediatric Patients
• 9.3. Geriatric Patients

10. Peritoneal Dialysis Market, by Application

• 10.1. Acute Kidney Injury
• 10.2. Chronic Kidney Disease
• 10.3. End-Stage Renal Disease

11. Peritoneal Dialysis Market, by End User

• 11.1. Hospitals
• 11.2. Dialysis Centers
• 11.3. Home Care Settings
• 11.4. Research & Academic Institutes

12. Peritoneal Dialysis Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Peritoneal Dialysis Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Peritoneal Dialysis Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Advin Health Care
• 16.2. Angiplast Pvt. Ltd.
• 16.3. B. Braun Medical Ltd
• 16.4. Baxter International, Inc.
• 16.5. Becton, Dickinson and Company
• 16.6. Cook Group Incorporated
• 16.7. Diaverum AB by M42
• 16.8. Fresenius Medical Care AG
• 16.9. Huaren Pharmaceutical Co., Ltd.
• 16.10. JDmeditech
• 16.11. JMS Co., Ltd.
• 16.12. Medionics International Inc.
• 16.13. Mitra Industries
• 16.14. Mozarc Medical
• 16.15. Opterion Health AG
• 16.16. PFM Medical, Inc.
• 16.17. Renax Biomedical Technology Co., Ltd.
• 16.18. Renfrew Group International
• 16.19. Romsons Prime Private limited
• 16.20. Terumo Corporation
• 16.21. Toray Industries, Inc.
• 16.22. Vivance